The therapeutic potential of ANXV is broad since its target phosphatidylserine (PS) is a factor in several diseases.
Annexin Pharmaceuticals investor pages.
Annexin is a biotechnology company in clinical stage and a leader in the Annexin A5 area. The company is listed at First North, Stockholm, and is headquartered in Stockholm, Sweden.
21 Aug, 2024 - Pressrelease
The investigational new drug candidate ANXV demonstrated a favorable safety profile. Out of 14 subjects who received ANXV and were followed for 4 months, 12 improved or had stable disease…
30 Jul, 2024 - Pressrelease
Annexin Pharmaceuticals AB today announces publication of a scientific review article in the Special Issue “Novel Treatments and Technologies for Retinal Diseases” of the peer-reviewed Journal Pharmaceuticals. The review focuses…
30 May, 2024 - Regulatory pressrelease
NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND…
23 May, 2024 - Pressrelease
Annexin Pharmaceuticals AB (publ) announces that it is 10 years since the company was founded with the goal of developing Annexin A5 protein into a new medicine. One of the…
14 May, 2024 - Regulatory pressrelease
NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG-KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND OR…
07 May, 2024 - Regulatory pressrelease
25 Apr, 2024 - Pressrelease
Annexin Pharmaceuticals AB today announces that the last patient has been treated with the investigational new drug ANXV in the Phase 2a study that included a total of 15 patients…
28 Mar, 2024 - Regulatory pressrelease
08 Feb, 2024 - Pressrelease
Annexin Pharmaceuticals AB today announces that 6 out of 8 patients with the eye disease retinal vein occlusion (RVO) receiving the investigational drug candidate ANXV in the Phase 2a/proof-of-concept study…
18 Jan, 2024 - Pressrelease
Annexin Pharmaceuticals today announces that the company is participating at Redeye’s theme event Fight Cancer on January 24, 2024. CEO Anders Haegerstrand will present the latest development in the company’s…
18 Dec, 2023 - Regulatory pressrelease
30 Nov, 2023 - Regulatory pressrelease
28 Nov, 2023 - Regulatory pressrelease
23 Nov, 2023 - Pressrelease
Annexin Pharmaceuticals today announces that the first two patients who received the higher dose of 4 mg of the drug candidate ANXV in the company's clinical phase 2 study in…
14 Nov, 2023 - Pressrelease
Annexin Pharmaceuticals today announces that its drug candidate ANXV has been granted enhanced and extended patent protection by the US Patent and Trademark Office. The United States Patent and Trademark…
25 Oct, 2023 - Pressrelease
Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company's clinical phase 2 study in patients with retinal…
24 Oct, 2023 - Regulatory pressrelease
29 Sep, 2023 - Pressrelease
Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer…
11 Sep, 2023 - Pressrelease
Annexin Pharmaceuticals AB today announced that the company is participating at Redeye Investor Forum in Gothenburg on September 14, 2023, 18:00-20:00 CET. CEO Anders Haegerstrand will present the latest development…
24 Aug, 2023 - Pressrelease
Annexin Pharmaceuticals AB today announced that the company is participating at ProHearings’ Capital Markets Day on August 29, 2023, at 09:10 CET. CEO Anders Haegerstrand will present the latest…
11 Aug, 2023 - Regulatory pressrelease
Annexin Pharmaceuticals AB today announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase 2-study in retinal vein occlusion with the investigational…
18 Apr, 2023 - Regulatory pressrelease
Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient…
21 Mar, 2023 - Regulatory pressrelease
Annexin Pharmaceuticals AB (publ) has recruited Susanne Andersson as Chief Financial Officer (CFO). Susanne will take position as CFO at Annexin Pharmaceuticals during April 2023, joining the management…
18 Jan, 2023 - Pressrelease
STOCKHOLM January 18, 2023 Annexin Pharmaceuticals AB (publ) announces that Dr. Thibault, a medical oncologist with extensive global experience leading novel compounds through clinical development, will join as…
19 Dec, 2022 - Regulatory pressrelease
PRESS RELEASE 19 December 2022 The Board of Directors of Annexin Pharmaceuticals AB (publ) (”Annexin Pharmaceuticals” or the “Company”) has today, with the support of the…
14 Dec, 2022 - Pressrelease
STOCKHOLM December 14, 2022 Annexin Pharmaceuticals AB (Publ) ("Annexin" or "the Company") announces today that the Company was awarded the Innovation Award at the Ophthalmology Innovation Summit (OIS) in…
08 Nov, 2022 - Pressrelease
STOCKHOLM (8 November 2022) – Annexin Pharmaceuticals AB (publ) (Nasdaq First North Growth market) announces today that the first patient with retinal vein occlusion (RVO) has been dosed in the…
22 Apr, 2022 - Regulatory pressrelease
Annexin Pharmaceuticals AB (publ) announces that the U.S. Patent and Trademark Office has allowed an issue of the new patent, further strengthening the intellectual property and key coverage for the…
05 Apr, 2022 - Regulatory pressrelease
Annexin Pharmaceuticals has been given the go-ahead by FDA to start the planned phase 2 clinical trial with the drug candidate ANXV in patients with retinal vein occlusion (RVO).
03 Apr, 2022 - Regulatory pressrelease
Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in…
29 Mar, 2022 - Pressrelease
Annexin Pharmaceuticals AB (publ) announces that Dr Mario Fsadni, an ophthalmologist with extensive global experience from leading novel compounds through clinical development into marketed drugs, will join as a new…
19 Jan, 2022 - Regulatory pressrelease
Maastricht University Hospital receives approvals to start study with Annexin Pharmaceuticals drug candidate, ANXV, in patients with COVID19. STOCKHOLM, SWEDEN (January 19, 2022) – Annexin Pharmaceuticals AB (publ) announces that…
22 Nov, 2021 - Regulatory pressrelease
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONGKONG, SWITZERLAND, SINGAPORE, NEW ZEALAND, OR ANY OTHER…
08 Nov, 2021 - Regulatory pressrelease
28 Oct, 2021 - Regulatory pressrelease
20 Oct, 2021 - Regulatory pressrelease
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONGKONG, SWITZERLAND, SINGAPORE, NEW ZEALAND, OR ANY…
19 Oct, 2021 - Regulatory pressrelease
29 Sep, 2021 - Regulatory pressrelease
Annexin Pharmaceuticals and Collaborators Initiate a Clinical Study in Patients with Retinal Vein Occlusion (RVO) Using Fluorescent Labelled ANXV. STOCKHOLM, SWEDEN (September 29, 2021) – Annexin Pharmaceuticals AB (publ) (“Annexin”)…
21 Sep, 2021 - Regulatory pressrelease
18 May, 2021 - Regulatory pressrelease
Physicians in the Netherlands plan to start a COVID-19 study with Annexin Pharmaceuticals drug candidate ANXV and have to this end submitted an application to the local authority. Annexin Pharmaceuticals…
16 Feb, 2017 - Pressrelease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed tempus sem dapibus diam pharetra, eget eleifend enim tristique. Suspendisse potenti. Ut vitae velit eu nibh adipiscing dapibus ac eget eros.
16 Feb, 2017 - Regulatory pressrelease
No pressreleases where found for the selected filters.
